Total drug expenditures projected to increase in 2016

Total drug expenditures projected to increase in 2016

(HealthDay)—Total drug expenditures are expected to increase by 11 to 13 percent in 2016, according to a study published online in the American Journal of Health-System Pharmacy.

Glen T. Schumock, Pharm.D., M.B.A., Ph.D., from the University of Illinois at Chicago, and colleagues obtained expenditure data through calendar-year 2015. Based on a combination of quantitative analyses and expert opinion, the authors projected expenditures for 2016.

In calendar-year 2015, total U.S. prescription sales were $419.4 billion; an increase of 11.7 percent from 2014. In clinics and nonfederal hospitals, the researchers found that prescription expenditures totaled $56.7 billion and $33.6 billion, respectively, representing increases of 15.9 and 10.7 percent, respectively. In nonfederal hospitals, increased prices for existing drugs was the main driver of the growth in . In terms of 2015 expenditures, the hepatitis C combination drug ledipasvir-sofosbuvir was the main drug overall ($14.3 billion); infliximab was the top drug in both clinics and nonfederal hospitals. In 2015, specialty agents and older generics were the drugs with the greatest increases in expenditures. These agents are expected to influence spending in 2016.

"We project an 11 to 13 percent increase in total drug expenditures overall in 2016, with a 15 to 17 percent increase in clinic spending and a 10 to 12 percent increase in ," the authors write. "Health-system pharmacy leaders should carefully examine local drug utilization patterns in projecting their own organization's in 2016."

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further

Medication spending may rise five percent this year

More information: Abstract
Full Text

Copyright © 2016 HealthDay. All rights reserved.

Citation: Total drug expenditures projected to increase in 2016 (2016, July 25) retrieved 4 December 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors